An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.

[1]  S. Weintraub,et al.  Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. , 2006, Prostaglandins & other lipid mediators.

[2]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[3]  C. Brosnan,et al.  Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Reynet,et al.  Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. , 2006, Cell metabolism.

[5]  A. Schulze-Bonhage,et al.  Fatty acid amidohydrolase in human neocortex—activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids , 2005, Neuroscience Letters.

[6]  B. Cravatt,et al.  The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400377-JLR200 , 2005, Journal of Lipid Research.

[7]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[8]  N. Stella.  Cannabinoid signaling in glial cells , 2004, Glia.

[9]  M. Kliot,et al.  Endocannabinoids accumulate in spinal cord of SOD1G93A transgenic mice , 2004, Journal of neurochemistry.

[10]  T. Möller,et al.  P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[12]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[13]  D. Greenberg,et al.  Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility , 2003, The Journal of Neuroscience.

[14]  K. Waku,et al.  Ether‐linked analogue of 2‐arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species , 2003, Journal of neurochemistry.

[15]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[16]  M. Maccarrone,et al.  Quantification of anandamide content in animal cells and tissues: the normalization makes the difference , 2002, Lipids in Health and Disease.

[17]  A. Finazzi-Agro’,et al.  Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. , 2002, The Biochemical journal.

[18]  T. Möller,et al.  Astrocytes in Culture Produce Anandamide and Other Acylethanolamides* , 2002, The Journal of Biological Chemistry.

[19]  F. Bymaster,et al.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[20]  A. Finazzi-Agro’,et al.  Anandamide degradation and N‐acylethanolamines level in wild‐type and CB1 cannabinoid receptor knockout mice of different ages , 2001, Journal of neurochemistry.

[21]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Bisogno,et al.  The FASEB Journal express article 10.1096/fj.00-0399fje. Published online December 8, 2000. Endocannabinoids control spasticity in a multiple sclerosis model , 2022 .

[23]  M. Maccarrone,et al.  Gas chromatography–mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture , 2001, Journal of neurochemistry.

[24]  C. Breivogel,et al.  Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. , 2000, European journal of pharmacology.

[25]  J. Walker,et al.  Pain modulation by release of the endogenous cannabinoid anandamide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Di Marzo,et al.  Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period , 1999, Synapse.

[27]  L. Parsons,et al.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.

[28]  T. Bisogno,et al.  Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. , 1999, Biochemical and biophysical research communications.

[29]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[30]  K. Waku,et al.  Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. , 1998, Archives of biochemistry and biophysics.

[31]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[32]  J. Turk,et al.  Isotope Dilution Mass Spectrometric Measurements Indicate That Arachidonylethanolamide, the Proposed Endogenous Ligand of the Cannabinoid Receptor, Accumulates in Rat Brain Tissue Post Mortem but Is Contained at Low Levels in or Is Absent from Fresh Tissue* , 1996, The Journal of Biological Chemistry.

[33]  P. C. Schmid,et al.  Occurrence and postmortem generation of anandamide and other long‐chain N‐acylethanolamines in mammalian brain , 1995, FEBS letters.

[34]  D. Piomelli,et al.  Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. , 1995, Prostaglandins, leukotrienes, and essential fatty acids.

[35]  K. Mackie,et al.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.

[36]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[37]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[38]  R. Mechoulam,et al.  Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. , 1994, European journal of pharmacology.

[39]  S. Almog,et al.  Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. , 1993, Journal of medicinal chemistry.

[40]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[41]  L. Matsuda,et al.  Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. , 1992, Molecular pharmacology.

[42]  T. Sugiura,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.